Erratum: Make or break for costimulatory blockers

Article metrics

Nat. Biotechnol. 22, 145–147 (2004).

On p. 145, CTLA4-Ig is described as having achieved “outstanding phase 3 results.” In fact, the data were from a phase 2 trial.

Additional information

The online version of the original article can be found at 10.1038/nbt0204-145

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Garber, K. Erratum: Make or break for costimulatory blockers. Nat Biotechnol 22, 341 (2004) doi:10.1038/nbt0304-341c

Download citation

Further reading